Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083242 | 1.00 | MGLL (0.34) | MGLLPREPFAPAAK1KDM1A | |
| SCHEMBL13078895 | 0.89 | DPP4 (0.38) | MGLLPREPFAPAAK1KDM1A | |
| SCHEMBL3744329 | 0.89 | DPP4 (0.38) | MGLLPREPFAPAAK1KDM1A | |
| SCHEMBL8080997 | 0.88 | PREP (0.35) | MGLLPREPFAPAAK1KDM1A | |
| SCHEMBL3755810 | 0.85 | PREP (0.34) | MGLLPREPFAPAAK1KDM1A | |
| SCHEMBL3742876 | 0.85 | ELOVL6 (0.39) | MGLLAAK1 | |
| SCHEMBL3736510 | 0.82 | MGLL (0.39) | MGLLPREPFAPAAK1TAS1R3 | |
| SCHEMBL3738226 | 0.82 | MGLL (0.39) | MGLLPREPFAPAAK1TAS1R3 | |
| SCHEMBL3748577 | 0.81 | MGLL (0.38) | MGLLPREPFAPAAK1TAS1R3 | |
| SCHEMBL3744735 | 0.80 | DPP4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | MGLL 1847/4885PREP 32/4885FAP 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.